Like all conventional DCs, DC3 activate CD8 T cells, but is especially potent in inducing CD8+ CD103+ tissue-resident memory T cells (TRM) and correlated with TRM accumulation in breast cancer (51). The gene discussed is CD8A; the disease is breast carcinoma.